Lin Li
Sichuan University
PoloxamerVacuoleTargeted drug deliveryDrug carrierTFEBCellMolecular biologyAquaporinProinflammatory cytokineLiposomeChemistryExtracellular matrixMaterials scienceIn vitroIn vivoTransferrinSuperoxide dismutaseProstateGlomerulus (kidney)InflammationEndotheliumPaclitaxelEthylene glycolRheumatoid arthritisBasic fibroblast growth factorBiodistributionGliomaInflammatory bowel diseaseBlood–brain barrierBlockadeDeguelinProteinuriaDrug deliveryDrugAutoimmunityProstate cancerLysosomeBladder cancerGlomerulonephritisAngiogenesisDexamethasoneCancer immunotherapyNucleusPathogenesisCaprolactoneTargeted therapyDoxorubicinPopulationTransferrin receptorPinocytosisCancer researchp38 mitogen-activated protein kinasesStereochemistryMedicineZeta potentialPI3K/AKT/mTOR pathwayCell biologyPharmacology
7Publications
5H-index
96Citations
Publications 7
Newest
Abstract null null Current clinical agents for autoimmunity disorders treatment often cause substantial adverse effects and safety concerns, owing to non-specific immune modulation. Due to the prominent contribution of effector T cells in pathogenesis of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), and preferential location of co-stimulatory receptor-ligand pair OX40-OX40L at the inflamed sites, selectively targeting autoaggressive T cells by blockade OX40-OX40L, might represe...
Source
Abstract Glioma is one of the most common aggressive brain malignancies, but the treatment of glioma is still far from satisfying. The efficiency of chemotherapy – the major choice of glioma treatment – is severely limited by low chemotherapeutic agents delivery across blood-brain barrier (BBB) and low tumor retention. Therefore, a safe and effective drug delivery system to help chemotherapy agents traverse the BBB and accumulate at tumor sites is urgently needed. Paclitaxel (PTX) is one of the ...
13 CitationsSource
Abstract Glomerulonephritis related renal failure is a frequent cause of end-stage renal disease, and immunoglobulin A nephropathy (IgAN) is the most frequent type of primary glomerulonephritis. As damage induced by IgAN mostly attributes to inflammation responses, inhibiting inflammation in glomerulus can protect normal renal function and delay the onset of renal failure. Hence, reducing levels of p38 MAPK and p65 which are essential regulators in p38 MAPK and NF-κB related inflammation respons...
7 CitationsSource
Though plastic nanoparticles have already raised much concern for their potential impact on health, our understanding of their biological effects is still utterly limited. Here we demonstrate for the first time that carboxyl-modified polystyrene nanoparticles (CPS) could effectively inhibit ferroptosis as a result of reduced cellular ROS which was triggered by transcription factor EB (TFEB) nucleus translocation. In this process, CPS first entered cells via macropinocytosis, then CPS-containing ...
23 CitationsSource
#7Lin Li (Sichuan University)
Prostate cancer, one of the leading causes of disease and death in men all over the world, is challenging to treat. α-Enolase, a multifunctional protein, is overexpressed on human prostate carcinoma cells, and thereby it is a potential target for treatment of prostate cancer. In the current study, the pHCT74 peptide was used to construct a kind of highly targeted liposome (pHCT74-lipo) loaded with doxorubicin (pHCT74-lipo-Dox), which specifically targeted α-enolase on prostate tumour cells. Comp...
18 CitationsSource
#3Lin Li (Sichuan University)
Some bladder disease therapies can benefit from intravesical drug delivery, which involves direct instillation of drug into the bladder via a catheter, to attain high local concentrations of the drug with minimal systemic effects. Deguelin is a potential anticancer agent, however, its poor water solubility and neurotoxicity restrict its clinical application. To address these challenges, we investigated the promising application of deguelin in the intravesical therapy of bladder cancer by designi...
46 CitationsSource
Attempts to neutralise basic fibroblast growth factor (BFGF) have met some success in blocking neovascularisation. The authors describe an oral protein vaccine based on human BFGF encapsulated poly(e-caprolactone)epoly(ethylene glycol)epoly(e-caprolactone) (PCEC) nanoparticles. The human BFGF encapsulated PCEC nanoparticles (BFGF/PCEC) were monodisperse with the mean diameter of 142enm and can slow-released BFGF in vitro . After mice were orally immunised with four dosages of BFGF/PCEC nanoparti...
3 CitationsSource